Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Leukemia 17Leukemia, Promyelocytic, Acute 10Multiple Myeloma 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 7Neoplasms, Plasma Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Anemia, Refractory, with Excess of Blasts 4Neuroblastoma 3Neoplasms 3Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Leukemia, Monocytic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Hepatocellular 3Blast Crisis 3Testicular Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Liver Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Arsenic Trioxide × Clear all
NCT00128596 2017-04-27

Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

University of Pittsburgh

Phase 2 Completed
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02956772 2017-02-23

Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

Hunan Provincial People's Hospital

Phase 2 Unknown
190 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00582400 2016-02-19

A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver

The University of Texas Medical Branch, Galveston

Phase 2 Terminated
9 enrolled 7 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡